Periodic Reporting for period 1 - REGHA (Medical device combining viscosupplementation with pharmacological active molecule to regenerate cartilage in degenerative or traumatic osteoarthritis.)

Regulaxis is a French biotech company developing a regenerative innovative medicine : Reg-O3,providing a new hope for patients affected by OsteoArthritis (OA), with a First in Class Mechanism of Action.H2020 SME Phase 1 granting allowed us to significantly accelerate several...